vs
BANCFIRST CORP（BANF）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是BANCFIRST CORP的1.1倍（$207.3M vs $181.0M），BANCFIRST CORP净利率更高（32.9% vs -62.0%，领先94.9%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 11.1%），BANCFIRST CORP自由现金流更多（$237.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.5%）
BancFirst Corporation是总部位于美国俄克拉荷马州的金融服务控股公司，旗下共运营三家附属银行：俄克拉荷马州特许银行BancFirst，以及得克萨斯州特许的Pegasus银行和沃辛顿银行，为两地市场提供多元金融服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BANF vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $181.0M | $207.3M |
| 净利润 | $59.5M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 41.6% | -54.7% |
| 净利率 | 32.9% | -62.0% |
| 营收同比 | 11.1% | 25.9% |
| 净利润同比 | 5.3% | 3.5% |
| 每股收益（稀释后） | $1.75 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $181.0M | $207.3M | ||
| Q3 25 | $175.5M | $159.9M | ||
| Q2 25 | $169.3M | $166.5M | ||
| Q1 25 | $164.8M | $139.3M | ||
| Q4 24 | $162.9M | $164.6M | ||
| Q3 24 | $163.7M | $139.5M | ||
| Q2 24 | $153.8M | $147.0M | ||
| Q1 24 | $151.0M | $108.8M |
| Q4 25 | $59.5M | $-128.6M | ||
| Q3 25 | $62.7M | $-180.4M | ||
| Q2 25 | $62.3M | $-115.0M | ||
| Q1 25 | $56.1M | $-151.1M | ||
| Q4 24 | $56.5M | $-133.2M | ||
| Q3 24 | $58.9M | $-133.5M | ||
| Q2 24 | $50.6M | $-131.6M | ||
| Q1 24 | $50.3M | $-170.7M |
| Q4 25 | 41.6% | -54.7% | ||
| Q3 25 | 45.0% | -106.9% | ||
| Q2 25 | 47.1% | -64.8% | ||
| Q1 25 | 43.1% | -102.6% | ||
| Q4 24 | 44.2% | -74.3% | ||
| Q3 24 | 45.2% | -94.6% | ||
| Q2 24 | 42.4% | -79.1% | ||
| Q1 24 | 42.5% | -151.9% |
| Q4 25 | 32.9% | -62.0% | ||
| Q3 25 | 35.7% | -112.8% | ||
| Q2 25 | 36.8% | -69.0% | ||
| Q1 25 | 34.0% | -108.5% | ||
| Q4 24 | 34.7% | -80.9% | ||
| Q3 24 | 36.0% | -95.7% | ||
| Q2 24 | 32.9% | -89.5% | ||
| Q1 24 | 33.3% | -156.8% |
| Q4 25 | $1.75 | $-1.28 | ||
| Q3 25 | $1.85 | $-1.81 | ||
| Q2 25 | $1.85 | $-1.17 | ||
| Q1 25 | $1.66 | $-1.57 | ||
| Q4 24 | $1.68 | $-1.34 | ||
| Q3 24 | $1.75 | $-1.40 | ||
| Q2 24 | $1.51 | $-1.52 | ||
| Q1 24 | $1.50 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $-80.0M |
| 总资产 | $14.8B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $421.0M | ||
| Q3 25 | — | $202.5M | ||
| Q2 25 | — | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
| Q4 25 | $1.9B | $-80.0M | ||
| Q3 25 | $1.8B | $9.2M | ||
| Q2 25 | $1.7B | $151.3M | ||
| Q1 25 | $1.7B | $144.2M | ||
| Q4 24 | $1.6B | $255.0M | ||
| Q3 24 | $1.6B | $346.8M | ||
| Q2 24 | $1.5B | $432.4M | ||
| Q1 24 | $1.5B | $140.3M |
| Q4 25 | $14.8B | $1.5B | ||
| Q3 25 | $14.2B | $1.2B | ||
| Q2 25 | $14.0B | $1.3B | ||
| Q1 25 | $14.0B | $1.3B | ||
| Q4 24 | $13.6B | $1.5B | ||
| Q3 24 | $13.3B | $1.5B | ||
| Q2 24 | $12.7B | $1.6B | ||
| Q1 24 | $12.6B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $285.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $237.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 130.9% | -48.6% |
| 资本支出强度资本支出/营收 | 26.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.79× | — |
| 过去12个月自由现金流最近4个季度 | $430.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $285.3M | $-99.8M | ||
| Q3 25 | $75.4M | $-91.4M | ||
| Q2 25 | $78.1M | $-108.3M | ||
| Q1 25 | $77.0M | $-166.5M | ||
| Q4 24 | $261.2M | $-79.3M | ||
| Q3 24 | $77.6M | $-67.0M | ||
| Q2 24 | $100.2M | $-77.0M | ||
| Q1 24 | $66.3M | $-190.7M |
| Q4 25 | $237.0M | $-100.8M | ||
| Q3 25 | $63.7M | $-92.7M | ||
| Q2 25 | $64.4M | $-110.7M | ||
| Q1 25 | $65.6M | $-167.8M | ||
| Q4 24 | $224.5M | $-79.5M | ||
| Q3 24 | $72.4M | $-68.6M | ||
| Q2 24 | $94.1M | $-79.0M | ||
| Q1 24 | $56.1M | $-193.9M |
| Q4 25 | 130.9% | -48.6% | ||
| Q3 25 | 36.3% | -58.0% | ||
| Q2 25 | 38.0% | -66.5% | ||
| Q1 25 | 39.8% | -120.5% | ||
| Q4 24 | 137.8% | -48.3% | ||
| Q3 24 | 44.2% | -49.2% | ||
| Q2 24 | 61.2% | -53.7% | ||
| Q1 24 | 37.1% | -178.2% |
| Q4 25 | 26.7% | 0.5% | ||
| Q3 25 | 6.7% | 0.8% | ||
| Q2 25 | 8.1% | 1.5% | ||
| Q1 25 | 6.9% | 1.0% | ||
| Q4 24 | 22.5% | 0.1% | ||
| Q3 24 | 3.2% | 1.2% | ||
| Q2 24 | 3.9% | 1.4% | ||
| Q1 24 | 6.8% | 3.0% |
| Q4 25 | 4.79× | — | ||
| Q3 25 | 1.20× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | 1.37× | — | ||
| Q4 24 | 4.62× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BANF
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
